Insider Selling: Billiontoone (NASDAQ:BLLN) Insider Sells 20,000 Shares

Posted by Francis Steltz on Sep 10th, 2026

Billiontoone, Inc. (NASDAQ:BLLN – Get Free Report) insider Thomas Lynch sold 20,000 shares of Billiontoone stock in a transaction dated Tuesday, September 8th. The stock was sold at an average price of $99.99, for a total value of $1,999,800.00. Following the completion of the sale, the insider directly owned 700 shares in the company, valued at $69,993. This trade represents a 96.62% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Billiontoone Price Performance

Billiontoone stock traded down $0.65 during midday trading on Thursday, reaching $98.51. 729,077 shares of the stock traded hands, compared to its average volume of 562,068. The stock has a market cap of $4.65 billion and a P/E ratio of 141.66. The stock’s fifty day moving average is $112.07 and its 200-day moving average is $95.79. The company has a quick ratio of 11.31, a current ratio of 11.69 and a debt-to-equity ratio of 0.17. Billiontoone, Inc. has a 12 month low of $61.96 and a 12 month high of $150.44.

Billiontoone (NASDAQ:BLLN – Get Free Report) last released its quarterly earnings data on Wednesday, August 5th. The company reported $0.15 earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of $0.15. The business had revenue of $109.45 million for the quarter. Billiontoone had a return on equity of 9.96% and a net margin of 8.04%. As a group, equities research analysts anticipate that Billiontoone, Inc. will post 0.83 EPS for the current year.

Analyst Ratings Changes

BLLN has been the topic of a number of recent research reports. BTIG Research decreased their price target on shares of Billiontoone from $142.00 to $130.00 and set a “buy” rating on the stock in a research note on Thursday, August 6th. Guggenheim began coverage on shares of Billiontoone in a report on Monday, June 29th. They issued a “buy” rating and a $125.00 target price on the stock. Canaccord Genuity Group assumed coverage on shares of Billiontoone in a research report on Wednesday, September 2nd. They set a “buy” rating and a $120.00 target price on the stock. Zacks Research lowered Billiontoone from a “hold” rating to a “strong sell” rating in a research report on Monday, August 31st. Finally, JPMorgan Chase & Co. decreased their price objective on Billiontoone from $145.00 to $130.00 and set an “overweight” rating on the stock in a research report on Thursday, August 6th. Seven research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and two have given a Sell rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of “Hold” and an average price target of $125.88.

Get Our Latest Stock Analysis on BLLN

Institutional Investors Weigh In On Billiontoone

Several hedge funds and other institutional investors have recently modified their holdings of BLLN. UBS Group AG purchased a new position in Billiontoone during the 4th quarter valued at $2,586,000. Nano Cap New Millennium Growth Fund L P bought a new stake in shares of Billiontoone during the fourth quarter worth $82,000. Geode Capital Management LLC purchased a new stake in shares of Billiontoone during the fourth quarter valued at $6,716,000. Seven Grand Managers LLC bought a new position in shares of Billiontoone in the fourth quarter worth about $2,046,000. Finally, Norges Bank purchased a new position in Billiontoone in the 4th quarter worth about $818,000.

Billiontoone Company Profile

(Get Free Report)

BillionToOne (NASDAQ: BLLN) is a molecular diagnostics company that develops and commercializes high-precision genetic testing solutions based on single-molecule counting technology. The company’s platform is designed to detect and quantify rare genetic variants and chromosomal abnormalities from cell-free DNA, with a primary focus on applications in prenatal screening and other clinical genetic tests where sensitivity and specificity at very low allele fractions are critical.

BillionToOne’s offerings center on assay development and clinical testing workflows that enable non-invasive prenatal testing (NIPT) and targeted molecular diagnostics.

Insider Buying and Selling by Quarter for Billiontoone (NASDAQ:BLLN)

Receive News & Ratings for Billiontoone Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Billiontoone and related companies with MarketBeat.com's FREE daily email newsletter.